Andere talen Shanghai Junshi Biosciences Co., Ltd.

Aandelen

1877

CNE100003FF7

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:09:13 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,65 ^HKD	+3,88%		-6,31%	-50,36%

08/04	Junshi Biosciences krijgt goedkeuring voor registratie van toripalimab-injectie	MT
07/04	Shanghai Junshi Biosciences Co., Ltd. Kondigt de goedkeuring aan van de sNDA voor toripalimab voor de eerstelijns behandeling van nierkanker	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Junshi Biosciences Gets Nod to Register Toripalimab Injection	08/04
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	03/04
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	02/04
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	02/04
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates	29/03
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	29/03
Junshi Bio's 2023 Loss Widens, Misses Estimates	26/02
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Junshi Biosciences Proposes Share Buyback	02/02
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority	02/02
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	01/02
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	01/02
Shanghai Junshi Biosciences to Narrow Losses	31/01
Junshi Bio Inks 40 Million Yuan Deal With Shanghai Allink Biotherapeutics	31/01
Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	30/01
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer	18/01
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer	12/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Shanghai Junshi Biosciences Co., Ltd.

Aandelen

1877

CNE100003FF7

Andere talen

Filters